OncoBEAM testing for NSCLC

Monitoring resistance

Taus Á, Camacho L, Rocha P, et al. (2018) Dynamics of EGFR Mutation Load in Plasma for Prediction of Treatment Response and Disease Progression in Patients With EGFR-Mutant Lung Adenocarcinoma. Clin Lung Cancer. 19(5):387-394.e2.  Link: Pubmed

Krug AK, Enderle D, Karlovich C, et al. (2018) Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma. Annals of Oncology. 29(3):700-706. Links: Pubmed Free PDF

Karlovich C, Goldman JW, Sun MS, et al. (2016) Assessment of EGFR mutation status in matched plasma and tumor tissue of NSCLC patients from a phase 1 study of rociletinib (CO-1686). Clin Cancer Res. 2016 Jan 8. [Epub ahead of print] Link: Pubmed


Piotrowska Z, Niederst MJ, Karlovich CA, et al. (2015) Heterogeneity underlies the emergence of EGFR T790 wild-type clones following treatment of T790M-positive cancers with a third generation EGFR inhibitor. Cancer Discov. 5(7):713-22. Links: Pubmed Free PDF

Taus A, Hernandez A,  Del Carmen Vela M, et al. (2015) Monitoring treatment response in EGFR mutant non-small cell lung cancer patients using mutational load in circulating cell-free tumour DNA. J Clin Oncol 33, 2015 (suppl; abstr e19089) Link: Abstract

Thress K, Brant R, Carr TH, et al. (2015) EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer. 90(3):509-15. Links: Pubmed Free PDF

Thress K, Yang J,  Ahn M, et al. (2014) Levels of EGFR T790M in plasma DNA as a predictive biomarker for response to AZD9291, a mutant-selective EGFR kinase inhibitor. Annals of Oncology (2014) 25 (suppl_4): iv426-iv470. 10.1093/annonc/mdu349 Links: Abstract Poster